Evommune (EVMN) closed at $5.94 on November 3, 2026, down 1.2% from the previous close, on volume of 207,587 shares (30-day average 963,098).
Data as of November 3, 2026.
Analysts Conflicted on These NA Names: Evommune, Inc. (EVMN) and Arxis, Inc. Class A (ARXS)
TipRanks (Tue, 3-Nov 4:32 AM ET)
H.C. Wainwright Remains a Hold on Evommune, Inc. (EVMN)
TipRanks (Tue, 3-Nov 4:30 AM ET)
Evommune: Early-Stage Pipeline, Rising Competitive Bar Keep Mitchell Kapoor at Hold/Neutral
TipRanks (Thu, 29-Oct 8:45 AM ET)
Market Chameleon (Thu, 1-Oct 4:20 AM ET)
Business Wire (Thu, 1-Oct 8:00 AM ET)
Business Wire (Wed, 23-Sep 4:05 PM ET)
Business Wire (Tue, 8-Sep 5:43 PM ET)
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Business Wire (Thu, 6-Aug 4:05 PM ET)
Market Chameleon (Mon, 29-Jun 5:00 AM ET)
Evommune Secures $125 Million Private Placement Backed by Leading Healthcare Funds
Market Chameleon (Fri, 13-Feb 6:54 AM ET)
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
Evommune trades on the NYSE stock market under the symbol EVMN.
As of November 3, 2026, EVMN stock price declined to $5.94 with 207,587 million shares trading.
EVMN has a beta of 0.46, meaning it tends to be less sensitive to market movements. EVMN has a correlation of 0.00 to the broad based SPY ETF.
EVMN has a market cap of $215.58 million. This is considered a Small Cap stock.
Last quarter Evommune reported $0 in Revenue and -$.89 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.22.
The top ETF exchange traded funds that EVMN belongs to (by Net Assets): VTI, IWM, VXF, FESM, IWO.
EVMN support price is $5.63 and resistance is $6.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EVMN shares will trade within this expected range on the day.
